-
1 Comment
Oriola Oyj is currently in a long term downtrend where the price is trading 1.4% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.2.
Oriola Oyj's total revenue rose by 4.4% to $466M since the same quarter in the previous year.
Its net income has increased by 356.2% to $4M since the same quarter in the previous year.
Finally, its free cash flow grew by 50.0% to $41M since the same quarter in the previous year.
Based on the above factors, Oriola Oyj gets an overall score of 4/5.
| ISIN | FI0009014351 |
|---|---|
| Industry | Pharmaceutical Retailers |
| Sector | Healthcare |
| CurrencyCode | EUR |
| Exchange | F |
| Beta | 0.62 |
|---|---|
| Dividend Yield | 4.3% |
| Target Price | None |
| PE Ratio | 47.73 |
| Market Cap | 274M |
Oriola Oyj provides healthcare and wellbeing products in Sweden and Finland. It also offers vitamins, food and food supplements, sports nutrients, wound care, beauty, and makeup related products. The company offers distribution, licensed medicines, and dose dispensing services, as well as involved in research for pharmacies related products. The company serves pharmacies, healthcare, veterinarians, ecommerce, retail, and digital service sectors. Oriola Oyj is headquartered in Espoo, Finland.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for O5O.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
